Aspartic proteases plays very important role in posttranslational processing of proteins and many of them are important for organism viability. Here we report five different inhibitor compounds against two Aspartic proteases which are Catephsin D and Plasmepsin II. Cathepsin D and Plasmepsin II are drug targets for treatment of breast cancer and malaria respectively. It is also noted in the present study that the docking results of these compounds were good which ranges from -23.87 to -43.39 in case of Cathepsin D while from -22.31 to -31.68 in case of Plasmepsin II. Aspartic proteases Plasmepsin II catalyzes the initial step in the breakdown of hemoglobin by the Plasmodium falciparum, which causes a big percentage of malaria deaths. In this study, two compounds showed inhibition for Plasmepsin II and four compounds showed inhibition for Cathepsin D among five compounds 7223, 11994, 13161, 28427, 32656 (Compounds received from National Cancer Institute, New York, USA for this research). The compounds were further experimentally confirmed by enzyme inhibition studies after docking analysis. These compounds can be use in combination therapy to increase the resistance as antimalarial drugs and for breast cancer treatment.